Suda Pharmaceuticals Secures Australian Patent for Anagrelide
Category: #health  By Pankaj Singh  Date: 2020-09-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Suda Pharmaceuticals Secures Australian Patent for Anagrelide

The shares for Suda Pharmaceuticals were up by 13% after the company received a patent for Anagrelide from the Australian Patent Office. The patent is named as Prevention and Treatment of Metastatic Disease in Thrombocytotic Cancer Patients and will last through to December 2035. The endowment from the Japanese Patent Office follows the approval.

Suda Pharmaceuticals CEO, Dr. Michael Baker expressed his happiness about adding Australia to the list of regions which includes Europe and Japan, for which the patent for the new use of Anagrelide is granted.

Dr. Baker added that patents are important in drug development for the value creation process and this endowment from Australia strengthens the company’s capacity to maximize value from the Anagrelide program.

Anagrelide is used to treat blood disorders and is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) of the U.S.

According to the studies, the drug reduces the number of blood platelets and blocks the cancerous cell's movement towards the cells that produce platelets. Platelets play an important role in helping the growth and spread of cancer and defeating the immune response of the body toward cancer. Some studies also showed that the cancer cells can trigger chemicals sometimes to direct signals to produce more platelets in the body.

In a recent study completed at Covance in the U.K., it was found that the drug’s oral spray formulation can be a safer method to deliver Anagrelide in solid tumor patients. This way, the unwanted side effects of the present capsule formula can be reduced.

Suda Pharmaceuticals is the only company around the globe with patents for the use of Anagrelide to treat and prevent metastatic disease in the lungs or bones.

Suda Pharmaceuticals Ltd is an Australia-based leading pharmaceutical company that focuses on delivering medicines across the oral mucosa by utilizing its proprietary OroMist® technology.

 

Source: https://themarketherald.com.au/suda-pharmaceuticals-asxsud-receives-australian-patent-for-anagrelide-2020-09-08/

https://themarketherald.com.au/suda-pharmaceuticals-asxsud-receives-japanese-patent-for-anagrelide-2020-05-20/

https://sudapharma.com/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...